TPD52L1抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-5: 293T cells, 231 cells, PC3 cells, A549 cells, K562 cells, Primary antibody: P05439(TPD52L1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

The TPD52L1 antibody is a tool used to detect the Tumor Protein D52-Like 1 (TPD52L1), a member of the TPD52 protein family involved in cellular processes like vesicle trafficking, cell proliferation, and apoptosis. TPD52L1. encoded by the TPD52L1 gene, is overexpressed in various cancers, including breast, prostate, and lung cancers, making it a potential biomarker for tumor progression and therapeutic targeting. This protein interacts with signaling pathways such as mTOR and ERK, influencing cell survival and growth.

Antibodies against TPD52L1 are widely utilized in research to study its expression patterns, subcellular localization (e.g., Golgi apparatus, cytoplasmic vesicles), and functional roles through techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). They help validate TPD52L1’s involvement in oncogenesis, drug resistance, and metastasis. Commercial TPD52L1 antibodies are typically raised in rabbits or mice, with validation across specific applications and species reactivity (human, mouse, rat). Researchers prioritize antibodies with high specificity, sensitivity, and reproducibility to minimize cross-reactivity with homologous family members (TPD52. TPD52L2. TPD52L3).

Ongoing studies aim to clarify TPD52L1’s mechanistic contributions to disease, supporting its potential as a diagnostic or prognostic marker and a target for anticancer therapies.